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Tutkimuksen tausta ja tavoitteet: Hypertrofinen kardiomyopatia (HCM) on 
autosomaali-dominantisti periytyvä sairaus joka on sekä geno- että fenotyypiltään 
hyvin heterogeeninen. HCM on yksi yleisimmistä periytyvistä sydänsairauksista sekä 
erittäin merkittävä tekijä sydämen komplikaatioista johtuvissa äkkikuolemissa 
nuorilla aikuisilla. Taudille tyypillinen vasemman kammion- ja kammioiden välisen 
seinämän sydänlihaksen paksuuntuminen voi johtaa useisiin erimuotoisiin sydämen 
toiminnallisiin komplikaatioihin. Hoitoa HCM:aa vastaan ei ole vielä löydetty. Tämän 
tutkimuksen tavoitteena oli identifioida ja verrata yhdensuuntaisen mekaanisen 
venytyksen vaikutuksia HCM –potilaiden ja kontrollihenkilöiden ihmisen 
indusoiduista pluripotenteista kantasoluista erilaistettuihin sydänlihassoluihin. 
 
Tutkimusmenetelmät: Tutkimuksessa käytettiin neljää eri ihmisen fibroblasteista 
uudelleenohjelmoitua indusoitua pluripotenttia kantasolulinjaa (hiPSC) joista kolme 
oli HCM-potilasspesifisiä kantaen suomalaista MYBPC3-valtamutaatiota (Q1061X) ja 
yksi kontrollilinja terveestä henkilöstä. Näistä linjoista erilaistettuja sydänlihassoluja 
venytettiin yhdensuuntaisesti Flexcell®-laitteella, immunovärjättiin, kuvattiin ja 
analysoitiin. Immunovärjätyistä kuvista analysoitiin hiPS-soluista erilaistettujen 
sydänlihassolujen jakautumista, järjestäytymistä, monitumaisuutta, pinta-alaa, 
sarkomeeriproteiinien organisoitumista sekä kammio- ja eteisspesifisten 
sydänlihassolujen muodostumista. 
 
Tutkimustulokset: Venytettyjä ja venyttämättömiä iPS-soluista erilaistettuja 
sydänlihassoluja verrattiin keskenään. Venytys vähensi jakaantumista ja 
monitumaisuutta. Venytys indusoi pinta-alan kasvua villityypin soluissa, 
eteisspesifisten sydänlihassolujen muodostumista sekä järjestäytymistä venytyksen 
suuntaa vasten. Venytyksellä oli erilaisia vaikutuksia eri sarkomeeriproteiinien 
järjestäytymiseen. Verrattaessa HCM- ja kontrolli-sydänlihassoluja keskenään, 
jakautuminen ja järjestäytyminen olivat samaa luokkaa, monitumaisia sekä 
eteisspesifisiä HCM -sydänlihassoluja oli enemmän ja kontrollisolut olivat pienempiä 
pinta-alaltaan. 
 
Johtopäätökset: Yhdensuuntaisella mekaanisella venytyksellä on useita eri 
vaikutuksia hiPS-soluista erilaistettuihin sydänlihassoluihin. Mekaanisesti 
stimuloimalla hiPSC sydänlihassoluja voidaan saada kypsymään ja paremmin 
vastaamaan aikuisen kudoksen kypsiä sydänlihassoluja. 
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Background and aims: Hypertrophic cardiomyopathy (HCM) is genetically inherited 
autosomal-dominant disease with significant genotypic and phenotypic heterogeneity. 
HCM is one of the most common inherited cardiovascular disorders and the leading 
cause of sudden cardiac death (SCD) in young adults. Typically hypertrophy affects 
the left ventricle and interventricular septum and may eventually lead to various 
cardiac complications. No specific preventive therapy is available for HCM. The aim 
of this study was to identify and compare the effects of uniaxial mechanical strain on 
HCM –patient specific and control human induced pluripotent stem cell -derived 
cardiomyocytes. 
 
Methods: Four induced pluripotent stem cell (hiPSC) lines were used in this study. 
Three cell lines were HCM –patient specific carrying the Q1061X- Finnish founder 
mutation in MYBPC3 gene and one wild type cell line was generated from a healthy 
individual. Cardiomyocytes (CMs) were differentiated from the hiPSC lines by END-
2 method, stretched uniaxially by Flexcell®-apparatus, immunostained, imaged and 
analyzed. From immunostained images, hiPSC –derived CMs’ proliferation, 
alignment, multinucleation, area and sarcomere protein organization were analyzed. 
 
Results: Stretched and control hiPSC –derived CMs were compared. Stretching 
decreased proliferation and multinuclearism. Stretching induced growth of area in 
wild type CMs, formation of atrial CMs and alignment against the axis of the strain. 
Stretching had diverse effects on sarcomere protein organization. When HCM and 
wild type cells were compared, proliferation and alignment were similar, there were 
more multinuclear and atrial HCM CMs and wildtype CMs were smaller in area. 
 
Conclusions: Uniaxial mechanical stretch has diverse effects on hiPSC –derived 
CMs. By mechanical stimulation, hiPSC –derived CMs could be made more mature to 
better resemble native adult CMs. 
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 Abbreviations: 
 
o Action potential, AP 
o Adenylyl cyclase, AC 
o Alpha-myosin heavy chain, α-MHC 
o Alpha-tropomyosin, αTM 
o Atrial myosin light chain 2, MLC2a 
o Atrial natriuretic factor, ANF 
o Beta-myosin heavy chain, β-MHC 
o Beta-adrenergic receptors, β-AR 
o Big MAPK, BMK or ERK5 
o C-Jun N-terminal kinase, JNK 
o Ca2+/calmodulin-dependent kinase II, CaMKII 
o Cardiac troponin C, cTnC 
o Cardiac troponin I, cTnI  
o Cardiac troponin T, cTnT 
o Cardiomyocyte, CM 
o Cyclic adenosinemonophosphate, cAMP 
o Dilated cardiomyopathy, DCM 
o Electrocardiography, ECG 
o Excitation-contraction coupling, ECC 
o Extracellular signal-regulated kinase, ERK 
o G-protein coupled receptor, GPCR 
o GPCR receptor kinase, GRK 
o Histone deacetylase, HDAC 
o Human induced pluripotent stem cell, hiPSC 
o Hypertrophic cardiomyopathy, HCM 
o Magnetic resonance imaging MRI 
o Mitogen-activated protein kinase, MAPK 
o Mitogen-activated protein kinase kinase, MAPKK 
o Mitogen-activated protein kinase kinase kinase, MAPKKK 
o Myosin binding protein C, MyBP-C 
o Myosin essential light chain, ELC 
o Myosin regulatory light chain, RLC 
o Protein kinase A, PKA 
o Protein kinase Cα, PKCα 
o Ryanodine receptor, RyR 
o Reactive oxygen species, ROS 
o Restrictive cardiomyopathy, RCM 
o Sarcoplasmic reticulum, SR 
o Sudden cardiac death, SCD 
o Stretch activated channel, SAC 
o Ventricular myosin light chain 2, MLC2v 
o Wild type, WT 
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1. Introduction 
 
Hypertrophic cardiomyopathy (HCM) is genetically inherited autosomal-dominant 
disease with significant genotypic and phenotypic heterogeneity. HCM is one of the 
most common inherited cardiovascular disorders and the leading cause of sudden 
cardiac death (SCD) in young adults. Typically hypertrophy affects the left ventricle 
and interventricular septum and may eventually lead to various cardiac complications. 
No specific preventive therapy is available for HCM. (Ashrafian et al., 2003; Maron 
& Maron, 2013; Watkins et al., 2011.) 
 Several genes coding for sarcomeric proteins have been associated with HCM 
(Landstrom & Ackerman, 2010; Maron & Maron, 2013; Watkins et al., 2011). In 
Finland two founder mutations have been discovered (Jääskeläinen et al., 2013). 
These mutations are located in genes coding for α-tropomyosin (αTM, TPM1) and 
myosin binding protein C (MyBP-C, MYBPC3). HCM is thought to arise from 
myocardial dysfunction caused by defects in sarcomere proteins and/or aberrant 
cardiac remodeling (Ashrafian et al., 2003; Maron & Maron, 2013; Watkins et al., 
2011). The exact mechanisms are unknown. 
 In 2006 Takahashi and Yamanaka published a new way to create pluripotent 
stem cells by inducing mouse embryonic or adult fibroblasts using retroviral vector 
carrying transcription factors (Takahashi & Yamanaka, 2006). After their significant 
discovery, the same has been achieved with human somatic cells by several research 
groups all over the world (Kujala et al., 2012; Lan et al., 2013; Liang et al., 2013; Sun 
et al., 2012). Human induced pluripotent stem cells (hiPSCs) can be differentiated into 
any cell type of the human body, including cardiomyocytes (CMs) (Mummery et al., 
2012). hiPSCs offer a great platform for cardiac disease modeling and -drug 
screening, since there are no many human sources of cardiac tissue specimens 
available. However, hiPSC derived CMs are structurally and functionally immature 
(Keung et al., 2014; Robertson et al., 2013). 
 In this study, effects of uniaxial mechanical strain on HCM –patient specific 
and wild type (WT) hiPSC –derived CMs were studied. Four different hiPSC lines 
were exposed to uniaxial mechanical strain to analyze its effect on CMs’ proliferation, 
sarcomere proteins, alignment, multinucleation, atrial and ventricular cell formation 
and area. The HCM cell lines were carrying the MYBPC3 Finnish founder mutation. 
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2. Literature review 
 
2.1 Introduction to heart muscle 
The main function of the heart is to pump oxidized blood to peripheral circulation and 
deoxidized blood to the pulmonary circulation. Heart muscle, i.e. the myocardium, 
provides the contractile force to cause movement of the blood in the blood vessels by 
increasing pressure. To carry out this task, myocardium needs to act as a synchronized 
unit. CMs are the basic unit of the myocardium and they are linked to each other at 
intercalated discs via cell to cell connections known as connexins, which allow the 
action potential (AP) to travel from one cell to another (Bers 2001; Severs, 2000). 
This allows the functional syncytium of the myocardium. There are different kind of 
CMs in the myocardium: atrial and ventricular CMs, pacemaker cells and purkinje 
fiber cells. Even though they have many similarities, there are a few know 
differences. They have different AP rates, myofibrillar contractile forces depending 
on their purpose and also differences in protein expressions, for example different 
connexin isoforms. Pacemaker cells are located at the sinoatrial node and are 
responsible for the pacemaking of the heart. Purkinje fiber cells act as the conduction 
system for the AP. Ventricular CMs provide the most contractile force whereas 
pacemaker cells maintain the rhythm of the heart with weak contractile force. 
(Bootman et al., 2006; Dehaan & Eichna, 1961; Moorman & Christoffels, 2003; 
Severs, 2000.) In comparison with ventricular CMs, atrial CMs do not have transverse 
tubules (T-tubules) which means they have different calcium handling properties 
(Ayettey  & Navaratnam, 1978; Yamasaki et al., 1997). 
 
2.1.1. Excitation contraction coupling 
The pacemaker cells in sinoatrial node are responsible for maintaining the rhythm of 
the heart. They have the ability to contract without stimulation. The AP generated by 
them spreads along the conduction system to reach the myocardium. Every CM 
receives the AP because of the gap junctions. When AP reaches CMs cell membrane, 
it depolarizes and voltage-dependent calcium channel (ICa) opens letting Ca
2+
 -ions in 
to the cell. There are two types of ICa: L-type (ICa,L) and T-type (ICa,T) (Bers 2000; 
Bers 2001; Bers, 2008). ICa,T is activated at more negative membrane potential than 
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ICa,L, basically meaning it will be activated more easily. On the other hand, it 
inactivates more rapidly than ICa,L. These attributes allow more rapid cycle of 
contraction, of course with other factors, so it does not come as a surprise that ICa,T is 
mostly expressed in pacemaker and purkinje cells (Bers 2000; Bers 2001; Bers, 2008). 
 
 
Figure 1. Calcium transport in the excitation contraction coupling (ECC) in 
ventricular cardiomyocytes (Bers, 2000). Calcium transport at peripheral myocyte cell 
membrane (sarcolemma) includes Ca ATPase (ATP), Na/Ca exchanger (Na-CaX) and 
at T-tubular sarcolemma voltage dependent calcium channels (ICa) and Na-CaX. 
Ryanodine receptor (RyR) is at dyadic junctional position on sarcoplasmic reticulum 
(SR). RyRs contribute to the release of calcium from SR and SR Ca ATPase (SR 
ATP) to uptake of calcium from cytoplasm. The activity of SR Ca ATPase is 
regulated by phospholamban (PLB). Cytoplasmic free calcium binds to troponin C 
(TnC) on the thin filaments and allows the myofibrillar contraction. Calcium enters 
mitochondria via uniporter and is removed by Na-CaX. Intramitochondrial calcium 
activates ATP production. Na-K ATPase and Na/H exchanger (NaHX) contribute to 
the ion balance and potential of the cell. 
 
 Activation of ICa results in increased intracellular [Ca2+] which activates 
ryanodine receptors (RyRs). This results in the Ca
2+
 -flux out from the sarcoplasmic 
reticulum (SR), which acts as an internal Ca
2+
 storage of the cell (Bers 2000; Bers 
2001; Bers, 2008). This phenomenon is known as calcium-induced calcium-release. In 
ventricular myocytes, RyRs are mostly located at the SR membrane in the proximity 
of the T-tubules as junctional RyRs, whereas in atrial myocytes there are larger bulk 
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of non-junctional RyRs deeper in the cells because of the absence of T-tubules 
(Bootman et al., 2006; Chen-Izu et al., 2006). This creates slight differences in 
excitation-contraction coupling (ECC) between atrial and ventricular myocytes, such 
as positioning of ICa,L channels. Usually RyRs are located underneath the ICa,L 
channels creating dyadic junctions (Figure 1). Because of the lack of T-tubules, these 
dyadic junctions are present only at the cell membrane (sarcolemma) of the atrial 
myocytes, whereas in ventricular myocytes they are scattered throughout the T-tubule 
network. (Bootman et al., 2006; Chen-Izu et al., 2006.) For this reason, influx of 
calcium creates an uneven balance of intracellular [Ca
2+
] throughout the atrial 
myocytes after depolarization (Bootman et al., 2006). 
 There is also some calcium entry to the cells via Na/Ca exchanger antiporter 
membrane proteins, but the voltage dependent calcium channels carry out most of the 
task. Free calcium-ions inside the cell bind to troponin C (TnC), one of the three 
troponins creating the troponin-complex, resulting in a conformational change which 
allows myosin heads of the thick filament to bind to actins of the thin filament. This 
conformational change moves long tropomyosin filaments away from the blocking 
position of actins, resulting in increased myosin binding along the thin filament, 
called cooperative activation. (Bers 2000; Bers 2001; Bers, 2008.) 
 Sympathetic and parasympathetic nervous systems regulate the function of the 
heart muscle by neuroendocrine transmitters, hormones. β-adrenergic receptors (β-
AR) bind catecholamines (hormones) such as epinephrine (adrenaline) and 
norepinephrine (noradrenaline) which activate several downstream signaling 
pathways in CMs. The hormonal regulation results in altered inotropy, chronotropy 
and lusitropy (cardiac output, heart rate and relaxation of myocardium) of the CMs by 
altering the calcium handling inside the cell. (Brodde & Michel, 1999.) 
 For relaxation to occur, calcium must be exported from the cytoplasm outside 
of the cell and/or back to SR, to lower the [Ca
2+
] in the cytoplasm so that the calcium-
ions can dissociate from TnC and undo the conformational change to block the actins 
of thin filament again. Calcium can be transported out of the cell by Ca ATPase and 
Na/Ca exchanger, into SR by SR Ca ATPase and into mitochondria by Ca uniporter. 
SR Ca ATPase and, to a lesser extent, Na/Ca exchanger constitute the main two 
elements of lowering the cytoplasmic [Ca
2+
]. (Bers 2000; Bers 2001; Bers, 2008.) 
 Actomyosin ATPase and active transportation of ions are the two most major 
consumers of ATP in CMs (Bers, 2008). Mitochondria are the powerhouses of the 
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cell, so they must adapt to altering energy demands in CMs for example during 
excercise. Approximately 30% of CM volume is occupied by mitochondria (Bers, 
2000). Calcium can enter mitochondria via calcium uniporter, and indeed, 
intramitochondrial calcium concentration can activate ATP synthase and several 
dehydrogenases to increase ATP production. Calcium is removed from mitochondria 
by Na/Ca exchange. (Bers, 2008.) 
 
2.1.2. Sarcomere structure 
CMs are full of myofibrils which consist of consecutive sarcomeres, the contractive 
units which are separated by Z-discs (Figure 2) (Clark et al., 2002). Z-discs create a 
backbone for thin filaments and they consist of myofilament cross-linking proteins 
such as α-actinin (Chiu et al., 2010; Clark et al., 2002)). The thin filaments consist of 
actins and αTMs covering them along the filament (Bers, 2001; Clark et al., 2002). 
αTM is a long helical protein which covers seven actin proteins and overlaps slightly 
with another tropomyosin following it (Bers, 2001; Tardiff, 2011). 
 
 
Figure 2. Microscopic anatomy of the cardiac muscle showing the sarcomere and the 
sarcomeric proteins. The complex interaction of proteins driving the events taking 
place for the contraction and relaxation of the cardiac muscle shown. (Edited from 
Maron & Maron, 2013) 
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Along the thin filament, there are troponin complexes which are in close interactions 
with both actin and αTM. Troponin complex consists of three troponins: troponin I 
(TnI), troponin C (TnC) and troponin T (TnT) (Metzger & Westfall, 2004; Tardiff, 
2011). Thick filament consists of myosin rod from which myosin heads reach towards 
thin filament (Harris et al., 2011). Sliding of the thin and thick filaments along each 
other shortens the sarcomere bringing the two Z-discs closer to each other. The 
myofilaments itself do not shorten in length. The myosin heads are responsible for the 
interaction between the thick and thin filament and provide the contractile force. The 
myosin head consists of myosin heavy-, regulatory light- and essential light chains 
(MHC, RLC and ELC respectively) (Warrick & Spudich, 1987). MyBP-C acts as a 
cross-bridge between thick and thin filament proteins and it is thought to have 
regulative and structural properties in the sarcomere (Barefield et al., 2014). 
 
2.2. Hypertrophic cardiomyopathy 
HCM is a prevalent hereditary cardiac disease which prevalence is thought to be as 
high as 1:500 (Maron et al., 1995). Although, this is just an approximation and the 
number can be even greater, since all affected people carrying this genetically 
inherited disease are not diagnosed. The disease has been studied for over 50 years 
now, and the various genetic effectors discovered show that it is very heterogenous, 
both genetically and clinically. There are over 1400 genetic mutations discovered 
which cause HCM (Maron & Maron, 2013). These mutations are found in 11 or more 
genes most coding for sarcomeric proteins (Landstrom & Ackerman, 2010; Maron & 
Maron, 2013). Worldwide, most of the mutations are located in genes coding beta-
myosin heavy chain (β-MHC, MYH7) and MyBP-C (MYBPC3) (Maron & Maron, 
2013; Richard et al., 2003; Watkins et al 2011). In Finland, two founder mutations for 
HCM were recently discovered (Jääskeläinen et al., 2013). These mutations are 
located in genes coding for αTM (TPM1) and MyBP-C (MYBPC3). 
 
2.2.1. Pathology and signaling in HCM 
HCM is often linked to arrhythmia and SCD, especially in young competing athletes 
(Maron et al., 1980; Maron et al., 1986). In HCM, the heart muscle (myocardium) 
becomes enlarged because of the thickening of left ventricular and/or interventricular 
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septal myocardium characterized with myocyte disarray and fibrosis (Figure 3) 
(Maron & Maron, 2013; Watkins et al., 2011). In some cases there is also right 
ventricular thickening (Watkins et al 2011). The left ventricle wall thickness can vary 
a lot, from mild (13-15mm) to massive (>50mm) (Klues et al., 1995; Maron et al., 
2009). The methods used to diagnose HCM include electrocardiography (ECG), 
echocardiography and magnetic resonance imaging (MRI) of the heart (Maron & 
Maron, 2013). For the last ten years, the most effective treatment for HCM and 
prevention of SCD has been implantable defibrillators, whereas pharmacological 
treatment includes beta-blockers, verapamil and disopyramide (Maron & Maron, 
2013). However, specific treatment for HCM has not yet been discovered. 
 
 
Figure 3. Normal and hypertrophied heart. Atrial and left ventricular wall and 
interventricular septum wall (arrows) thickness increases in cardiac hypertrophy. 
(Edited from www.servier.com/powerpoint-image-bank) 
 
 
 The exact mechanism how the cardiac hypertrophy develops, is not perfectly 
clear. However, it is thought to be a combination of changes in calcium affinity of the 
thin filaments and CM energy consumption (Crilley et al., 2003; Robinson et al., 
2007). Mutations in genes coding sarcomeric proteins are thought to have a 
myofilament activating effect by increasing the calcium affinity on the thin filament, 
which then leads to hypercontractility and a greater energy consumption of the CM 
(Crilley et al., 2003; Robinson et al., 2007). Since calcium plays a key role in ECC in 
CMs, it is no surprise that the alterations in calcium kinetics cause aberrant energy 
consumption and metabolism. These events are thought to lead to the activation of 
signaling pathways which cause CMs to grow in size and cause hypertrophy (Lan et 
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al., 2013). On the other hand, there has been some evidence that some sarcomeric 
protein mutations could decrease the contractile force of the cardiac myofilaments 
(Lankford et al., 1995; Watkins et al., 1996). This kind of behavior could lead to a 
compensatory hypertrophy by forcing the CMs to accommodate to the lack of 
contractile force (Ashrafian et al., 2003). 
 Several signaling pathways related to hypertrophy have been studied (Figure 
4). β-ARs are a type of g-protein coupled receptors (GPCRs) responsible for many 
downstream events in cardiac signaling pathways. They activate adenylyl cyclase 
(AC) and increase intracellular cyclic adenosine monophosphate (cAMP) 
concentration which leads to increased CM inotropy, chronotropy and lusitropy by 
activating protein kinase A (PKA) (Brodde & Michel, 1999; Lohse et al., 2003; van 
Berlo et al., 2013). PKA phosphorylates key calcium handling proteins which then 
leads to aforementioned phenomena in CMs. This pathway may lose its effect if it is 
excessively activated during a long period of time, which then may partly affect the 
development of hypertrophy in cardiac muscle (van Berlo et al., 2013). Another effect 
of chronic β-AR stimulation is desensitization of the receptor which has negative 
effects on myocardium. GPCR receptor kinases (GRKs) phosphorylate β-ARs to 
which β-arrestins then bind, uncoupling the receptor from the G-proteins causing 
decreased receptor sensitivity (Gurevich & Gurevich, 2006; Lohse et al., 2003). 
Activation of protein kinase Cα (PKCα), which is induced by GPCRs, regulates 
intracellular calcium handling proteins and thus myofilament contraction (van Berlo 
et al., 2013). Even though PKCα does not directly cause cardiac hypertrophy, its 
expression is elevated in failing human hearts, hence its inhibition could provide a 
novel therapeutic strategy (Bowling et al., 1999; Dorn & Force, 2005; Hambleton et 
al., 2007). Intracellular calcium, calmodulin and reactive oxygen species (ROS) 
regulate the Ca
2+
/calmodulin-dependent kinase II (CaMKII), which acts, in addition to 
the same type of regulation as PKCα, as a gene transcription regulator by influencing 
histone deacetylases (HDACs) (Anderson et al., 2011; Erickson et al., 2008; Zhang et 
al., 2007). Also, the δB-isoform of CaMKII, which localizes in nucleus, is shown to 
induce atrial natriuretic factor (ANF) expression, which is considered as a marker for 
ventricular hypertrophy (Ramirez et al., 1997). HDACs are key regulators of 
epigenetics. They deacetylate lysine residues in histone tails which usually leads to a 
gene repression (Bush & McKinsey, 2010). However, this is not always the case, 
since there is some evidence about HDAC regulation leading to a gene activation 
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suggesting that deacetylation/acetylation ratio is fine tuning the expression levels 
(Wang et al., 2009). HDACs have been identified as regulators of cardiac growth and 
they have antihypertrophic effects, which could be used in novel therapeutic strategies 
(Bush & McKinsey, 2010). Mitogen-activated protein kinase (MAPK) pathway, even 
though well studied, is very complex and its effects are still quite poorly understood. 
It constitutes several subfamilies including extracellular signal-regulated kinases 
(ERKs), c-Jun N-terminal kinases (JNKs), p38 kinases, and big MAPK (BMK or 
ERK5) (Rose et al., 2010). The activation of MAPK leads to activation of a cascade 
of phosphorylations, where MAPK kinase kinase (MAPKKK) activates MAPK kinase 
(MAPKK) which in turn activates MAPK (Rose et al., 2010). This activation cascade 
responses to different stimuli and results in various outcomes, not to mention the 
complex regulatory system. Even though there are evidence that MAPK pathway 
induces hypertrophy in heart, the results are somewhat controversial, largely due to 
the complexity of the pathway and the great number of involved mediators in it (Rose 
et al., 2010). 
 
 
Figure 4. Signaling pathways underlying pathologic cardiac remodeling. (Edited from 
van Berlo et al., 2013) 
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2.2.2. From genotypes to phenotypes 
HCM is inherited through autosomal dominant pattern with incomplete age-related 
penetrance (Landstrom & Ackerman, 2010; Maron & Maron, 2013; Watkins et al., 
2011). Over 1400 mutations are found in over 11 genes, most coding for sarcomeric 
proteins, on top of which may be unique in each family (Landstrom & Ackerman, 
2010; Maron & Maron, 2013; Watkins et al., 2011). Every new HCM family member 
has 50% chance of getting the mutation. These numbers itself tell about the genetic 
heterogeneity of the disease. Worldwide, most of the mutations are found in genes 
coding for β-MHC (MYH7) and MyBP-C (MYBPC3), proportions being 25-35% each 
of all cases (Maron & Maron, 2013; Watkins et al., 2011). Mutations in the rest of the 
genes account only for 1-5% of the cases each (Maron & Maron, 2013; Watkins et al., 
2011). In Finland the two most common mutations are TPM1-D175N and MYBPC3-
Q1061X accounting for 6.5% and 11.4% of the HCM cases respectively (Jääskeläinen 
et al., 2013). 
 
Table 1. Genes associated with HCM and aberrant cardiac remodeling. (*) Finnish 
founder mutations. Their respective prevalences in Finland are 11.4 and 6.5%. (Bos 
and Ackerman, 2009; Jääskeläinen et al., 2013; Landstrom & Ackerman, 2010; 
Richard et al., 2003; Seidman & Seidman, 2011) 
Gene Protein Prevalence in HCM 
Thick filament 
MYH7 β-MHC 25-35% 
MYL2 Regulator myosin light chain 1-5% 
MYL3 Essential myosin light chain 1-5% 
MYBPC3 Myosin binding protein C 25-35%* 
MYH6 α-myosin heavy chain 1-5% 
TTN Titin 1-5% 
Thin Filament 
TPM1 α-tropomyosin 1-5%* 
TNNT2 Cardiac troponin T 1-5% 
TNNI3 Cardiac troponin I 1-5% 
TNNC1 Cardiac troponin C 1-5% 
ACTC α-actin 1-5% 
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Genes coding for sarcomeric proteins, which have been shown to cause HCM, are 
shown in Table 1. Other susceptible genes, such as ACTN2 coding for α-actinin, have 
also been found (Bos and Ackerman, 2009; Seidman & Seidman, 2011). The top five 
genes most prone to mutations, according to CG relative mutability, were shown to be 
TNNC1, TNNT2, MYH7, MYBPC3 and MYL2 suggesting that deamination of CpGs 
could be an important mechanism for mutation development (Meurs & Mealey, 
2008). MYH7 and MYBPC3 mutations account 60-70% of the HCM cases, which 
suggests a highlighted role of thick filament in development of HCM (Maron & 
Maron, 2013; Morita et al., 2006).  
 Mutations in MYBPC3 have been shown to cause familial HCM in elderly 
indicating a late onset of the disease whereas mutations in MYH7 and TNNT2 cause 
symptomatic HCM early in life (Niimura et al., 2002). There are numerous missense 
and nonsense mutations, deletions and insertions and splice site donor/acceptor 
mutations reported in MYBPC3 leading to a premature STOP-codon, reading frame 
shifts or even truncated protein (Harris et al., 2011). Despite mouse models showing 
truncated proteins lacking C-terminal myosin and titin binding sites, showing 
increased calcium sensitivity of tension and inadequate localization in sarcomeres, 
results from human biopsies have been in contradict, showing reduced amounts of 
MyBP-C, thus indicating its degradation caused by post-translational modification of 
misfold protein (Marston et al., 2009; van Dijk et al., 2009; Yang et al., 1999). This 
has led to a hypothesis that MYBPC3 truncation mutations cause HCM through 
haploinsufficiency. However, reduced MyBP-C amounts were also reported with a 
mutation in MYBPC3 leading to a single amino acid substitution (Marston et al., 
2009). Missense mutations leading to single amino acid substitutions cause more 
benign outcomes of HCM (Harris et al., 2011). MyBP-C includes domains C0-C10 
plus proline/alanine-rich linker sequence between C0 and C1 and a regulatory linker 
motif between C1 and C2 (Figure 5). The mutations occur throughout the MYBPC3 
gene except the linker sequence appears to somehow have tolerance to mutations, 
whereas there are a few mutation rich areas in the C3 sequence (Harris et al., 2011). 
Some of these mutations leading to single amino acid substitutions are thought to lead 
to MyBP-C malfunction or misfolding, whereas some mutations do not seem to affect 
the protein folding (Harris et al., 2011). Even though MyBP-C has been studied for 
almost 40 years, its functional domains’ relevancy in thick and thin filament 
interactions still remains controversial (Bhuiyan et al., 2012). Mutations in these 
19 
 
 
domains involving protein-protein interactions may have detrimental effects in 
MyBP-C and sarcomere function, leading to HCM. 
 
C0 PA C1 M C2 C3 C4 C5 C6 C7 C8 C9 C10 
 
Figure 5. Domains of MyBP-C. PA = proline/alaninen-rich linker sequence, M = 
phosphorylable regulatory linker motif. C1, C2 and C7-C10 are involved in protein-
protein interactions. Domain C3 has a few mutation “hot spots”. Domains C0-C10 all 
have tertiary structures whereas PA and M are linker domains. C6, C7 and C9 have 
fibronectin-like and the rest C-domains have immunoglobulin-like folds. 
 
 
Mutations in MYH7, a gene coding for β-MHC, were the first to be found as a causing 
factors for HCM by Jarcho et al. (1989) and Geisterfer-Lowrance et al. (1990). 
Eventually, more were found and they were found to account most of the HCM cases 
(Watkins et al., 1992; Woo et al., 2003). Most of them are related to four important 
structural and functional domains in the myosin head: actin binding site, ATP binding 
site, essential light chain binding interface and head–rod junction (Rayment et al., 
1995; Woo et al., 2003). Thus mutations cause different clinical outcomes depending 
on the site of the mutation in the MYH7 sequence (Fananapazir & Epstein, 1994; 
Niimura et al., 2002; Woo et al., 2003). Most of the mutations are missense mutations, 
some which may lead to a charge change of amino acid and cause structural and 
functional changes resulting in different clinical outcome and disease prognosis (Woo 
et al., 2003). The α-myosin heavy chain (α-MHC) is an isoform of β-MHC with 
distinct functional properties. Mutations in MYH6 were suggested to result in a 
different clinical outcome, a late onset of HCM by Niimura et al., (2002).  
 There are two isoforms of ELC and RLC, atrial and ventricular (Schiaffino & 
Reggiani, 1996). The ventricular isoform of ELC is linked to HCM. Mutations in 
MYL3, the gene coding ELC, are usually located in exons coding for EF-hand 
domains, which are part of Ca
2+
-binding domain superfamily (Harris et al., 2011). 
However, in ELC, these domains have lost their ability somewhere along the 
evolution to bind these divalent cations. Despite the fact, biopsies from patients with 
mutation in ELC area coding for the EF-hand domain seem to have altered contractile 
functions (Poetter et al., 1996). The atrial and ventricular isoforms of RLC are also 
known as MLC2a and MLC2v respectively. In MYL2, the gene coding RLC, there are 
splice site acceptor- and missense mutations reported linked to HCM (Harris et al., 
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2011). These mutations affect mainly two domains: an EF-hand domain which binds 
Ca
2+
 and Mg
2+
 and a highly conserved N-terminal serine residue which mediates 
positive inotropic and chronotropic effects when phosphorylated (Colson et al., 2010; 
Harris et al., 2011). The mutations affect these domains’ abilities to perform which 
alters their aforementioned attributes. 
 Almost 100 independent mutations in thin filament proteins are found to cause 
HCM (Tardiff, 2011). Like in thick filament proteins, in thin filament mutations in 
different locations also result in various different clinical outcomes. From thin 
filament proteins, αTM, actin, cTnC, cTnI and cTnT have been associated with HCM. 
Although, some mutations in cTnI and cTnT have been associated with another two 
types of cardiac hypertrophy: dilated cardiomyopathy (DCM) and restrictive 
cardiomyopathy (RCM) (Tardiff 2011). cTnT was one of the first thin filament 
proteins shown to cause HCM when mutated (Lin et al., 1996; Morimoto et al., 1998; 
Redwood et al., 2000; Watkins et al., 1995). It is a key protein acting as an adapter 
between the troponin-complex and α-TM and actin. There are two alfa-helical 
domains in cTnT: the N-terminal αTM binding domain and troponin-complex (cTnI 
and cTnC) binding domain closer to the C-terminus. Mutations in cTnT causing HCM 
have been identified to localize to the N-terminal domain resulting in increased Ca
2+
 
sensitivity of myofilament activation (Tardiff, 2011). Because of the important role of 
cTnT in myofilament activation, it may not be a surprise that the mutations in this 
protein result in severe clinical outcome of SCD, but, however, at the same time to a 
relatively mild left ventricular hypertrophy (LVH) (Watkins et al., 1995). The latter 
though may partly explain the relatively low frequency of cTnT mutations linked to 
HCM, since LVH is a characteristic feature of HCM and therefore patients with 
mutations in cTnT do not appear in study cohorts as much. 
 cTnC and cTnI create the essential functional part of the troponin-complex 
responsible for Ca
2+
 induced myofilament activation. There are three Ca
2+
 binding 
sites in TnC of which the two locating in the N-terminal lobe of the protein regulate 
interaction with TnI. In the presence of calcium, TnI binds to TnC rather than actin of 
thin filament, thus not blocking the myosin actin interaction. Even though the 
importance of cTnI in troponin-complex, mutations in it are very heterogenous and 
result in various disease patterns (Mogensen et al., 2004). From the structural point of 
view, most of the mutations are clustered in the highly charged inhibitory region and 
αTM binding mobile domain in the TNNI3 amino acid -sequence (Tardiff, 2011). 
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These two regions are the ones that interact with either TnC or actin depending on the 
presence of calcium. Therefore it is no surprise that HCM causing mutations in these 
regions often lead to increase in Ca
2+
 sensitivity of the acto-myosin ATPase, which 
transforms the chemical energy of ATP to mechanical work of the sliding filaments 
(Tardiff, 2011). 
 αTM consists of two alpha-helical chains arranged as coiled-coil. It stabilizes 
the actin structures and cooperatively with other αTMs acts as a regulator of the 
myofilament activation by blocking or revealing the actin for the myosin depending 
on the Ca
2+
 concentration. Mutations causing HCM in TPM1 have been found to 
cluster in two regions which are responsible for actin and troponin-complex 
interactions (Tardiff, 2011). These mutations are also thought to lead into an increased 
Ca
2+
 sensitivity of myofilament activation (Tardiff, 2011). Clinical outcome varies 
greatly among patients having TPM1 mutations. 
 There are also other genes associated with HCM causing mutations which do 
not code for myofilament proteins, such as LIM binding domain 3 (LBD3), muscle 
LIM protein (CSRP3), telethonin (TCAP), vinculin/metavinculin (VCL), myozenin 2 
(MYOZ2), juctophilin-2 (JPH2) and phospholamban (PLN) (Bos and Ackerman, 
2009). Frequencies of the mutations in these genes are usually very low. 
 Genetic heterogeneity of HCM rises from two different things. First, the SCD 
in young adults acts kind of as a natural selection to delete these HCM mutations from 
populations. Second, larger genes attract more mutations because they are supposed to 
happen completely randomly in the genome (Seidman & Seidman, 2011). 
Additionally, the role of founder mutations in geologically and sociologically isolated 
populations is increased because of the more homogenous gene pool. More 
interestingly, the founder mutations almost always include MYBPC3 mutations 
resulting in expression of truncated protein (Seidman & Seidman, 2011). This 
indicates that the other HCM mutations may have more serious clinical outcome of 
the disease than founder mutations. 
 Phenotypic variability is high in HCM (Maron & Maron, 2013; Seidman & 
Seidman, 2011; Watkins et al., 2011). Even within the members of the same family 
phenotype may vary depending on genetic, allelic and epigenetic features, not to 
mention environmental aspects. Earlier studies reported severe forms of HCM but in 
the present, with better knowledge and diagnostics of the disease, most of the cases 
feature only mild or atypical symptoms (Watkins et al., 2011). Penetrance of HCM 
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increases with age, but the onset is observed by peaks both during childhood and mid-
adulthood (Watkins et al., 2011). The left ventricular wall undergoes remodeling 
during the early phase (age <17 years) of life which after tend to complete upon 
physical maturation (Maron & Maron, 2013). However, there may be delayed onset of 
HCM later in the ages of >30 years and beyond, but usually the outcome stays quite 
modest (Maron & Maron, 2013). The question is why children remain asymptomatic. 
 
2.2.3. Finnish founder mutations 
Founder mutation causing HCM has been discovered in Netherlands, Japan, South 
Africa and Finland (Alders et al., 2003; Jääskeläinen et al., 2013; Kubo et al., 2005; 
Moolman-Smook et al., 1999). These kind of mutations may have great impact on the 
disease in genetically isolated, less heterogenic populations, such as Finnish. In 
Finland indeed, there are two founder mutations reported: D175N missense mutation 
in the gene coding αTM (TPM1) and Q1061X nonsense mutation in the gene coding 
myosin-binding protein C (MYBPC3) (Jääskeläinen et al., 1998; Jääskeläinen et al., 
2002). Together these two mutations account for almost 18% of all HCM cases in 
Finland. 
 The reason for why these two mutations are not found to be common in other 
studied populations around the world, is thought to be the genetic isolation of Finnish 
population, which has allowed the enrichment of these two particular mutations in 
Finnish gene pool (Jääskeläinen et al., 2013). However, regional differences in 
prevalence between these two mutations are seen inside Finnish borders. Also, the 
size of the study group allows only rough estimations, but in the future, more 
screenings are expected to be carried out. 
 
2.3. Introduction to mechanotransduction 
Cell membrane, nucleus and all organelles are connected by a network of cytoskeletal 
actin filaments and microtubules. Focal adhesion complexes associated with integrins 
sense the signals coming from extracellular matrix (ECM), which leads to 
modifications in cytoskeletal scaffold (Chen, 2008). The local mechanical stimulus at 
the cell membrane becomes propagated through a series of force-dependent 
interactions which activates signaling pathways inside the cell through 
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mechanotransduction (Chen, 2008). It is known that mechanical stimulus is important 
for tissue growth, development and maintenance. Right kind of mechanical stimulus 
could be even used to drive cell/tissue differentiation into a desirable direction, since 
mechanical forces are known also to affect cellular signaling, gene expression and cell 
function (Chen, 2008). 
 
2.3.1. Mechanotransduction in cardiomyocytes 
Transduction of physical force to a chemical signal can occur through protein 
conformational changes. These proteins often have linkages to the intracellular 
cytoskeleton and/or ECM which amplify the signal to the transducers (Orr, 2006). 
Stretch activated ion channels (SACs), integrins, ECM and focal adhesion kinases 
may all contribute to the sensing of mechanical stimuli in CMs (Lammerding et al., 
2004). SACs play a major role in stretch activated currents in non-selective cation 
transportation. It has been shown that cariomyocytes from different species respond to 
mechanical strain with sarcolemma depolarization, AP prolongation and extra systoles 
(Kamkin et al., 2000; Kamkin et al., 2003). Integrins are a family of heterodimers 
consisting of 18 different α- and 8 different β-subunits. They have large extracellular 
ECM binding- and smaller intracellular cytoskeleton binding domain. The 
intracellular domain can also bind to signaling molecules such as focal adhesion 
kinase (FAK) and GTPases Rho and Rac (Lammending et al., 2004). Signaling via 
integrins work both ways, outside-in and inside-out. They can transmit the signal 
directly via conformational change or indirectly via parts cytoskeleton (Lammerding 
et al., 2004). The transmitters of mechanical force in CMs have been also found to 
include complexes which include vinculin, talin and laminin in addition to integrins 
(Lammerding et al., 2004).  
 Cardiomyocytes react with transient and long-term responses to various 
mechanical stimuli to stabilize their environment (Lammerding et al., 2004). Calcium 
handling can be an example of a transient and structural remodeling of a long term 
responses. CMs can harness the energy from changes in mechanical environment and 
stimuli to convert them into growth signals which then can lead to parallel sarcomere 
deposition and hypertrophy (Sadoshima and Izumo, 1997). In mice stretch 
activation/stressing of CMs has been shown to induce hypertrophy via increased 
protein synthesis, gene activation and several signaling pathway activation 
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(Sadoshima and Izumo, 1997). Paracrine and autocrine growth factors are supposed to 
be major contributors in the pathogenesis of stretch induced hypertrophic cell growth. 
In rat CMs, secretion of angiotensin II, endothelin-1 and basic fibroblast growth factor 
(FGF) are shown to be induced by mechanical stress (Sadoshima and Izumo, 1997). 
Comparing the responses of mechanical stretching and angiotensin II induction in 
neonatal rat CMs, several similarities has been found, such as increases in protein 
synthesis and immediate early-, fetal- and growth factor -gene activation (Sadoshima 
and Izumo, 1997). There is also similarities in activation of second messengers of 
mechanical stretch and angiotensin II induction including several kinases and other 
molecules (Sadoshima and Izumo, 1997). According to these findings it appears to 
convey that angiotensin II is the primary mediator of stretch induced hypertrophy, at 
least in rat CMs.   
 Also, several other stretch activated signaling pathways have been identified in 
rat CMs: G-protein coupled-, MAPK, janus-associated kinase/signal transducers and 
activators of transcription- (JAK/STAT), PKC, phospholipase -, calcineurin- and 
intracellular calcium pathways (Lammerding et al., 2004; Sadoshima and Izumo, 
1997). The relevance of some of these in HCM are explained in previous chapter 
(2.2.2., Figure 3) MAPKs such as ERKs and JNKs phosphorylate substrates 
responsible for cell growth and differentiation (Sadoshima and Izumo, 1997). JAKs 
become phosphorylated upon ligand binding to cytokine receptors which lead to 
phosphorylation and further activation of STATs, which are transcription factors 
(Lammerding et al., 2004). GPCRs can also activate STATs which leads to gene 
activation. The role of calcium in CMs is explained in previous chapter (2.1.1.). 
Increase in intracellular calcium in CMs increases phospholipase C (PLC) activity, 
which leads to another downstream events (figure 3).  Calcineurin is activated by 
calcium/calmodulin and it activates JNK and PKC mediating calcium signaling in 
CMs (Lammerding et al., 2004). As we see, many stretch activated signaling 
pathways induce HCM, and that furthermore establishes the solid connection between 
these two events. 
 
2.4 Induced pluripotent stem cells 
In 2006 Takahashi and Yamanaka published a new way to produce pluripotent stem 
cells by inducing mouse embryonic or adult fibroblasts using retroviral vector 
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carrying transcription factors (Takahashi & Yamanaka, 2006). There are four 
important transcription factors which are required for induction of pluripotency: Oct-
3/4, Sox2, c-Myc and KLF4 (Takahashi & Yamanaka, 2006). In 2007, induced 
pluripotent stem cells (iPSCs) were generated from adult human somatic cells 
(Takahashi et al., 2007). Human iPSCs (hiPSCs) allow negating the ethical issues 
arising from the use of human embryonic stem cells (hESCs) in research. Also, they 
allow easier development of patient- or disease specific cell lines, which offers a great 
tool for drug screening or to study disease mechanisms. hiPSCs are especially useful 
to study genetically inherited diseases affecting tissues which are difficult to acces, 
like heart. Several cardiovascular and neurological diseases have been studied with 
iPSCs: Long-QT –syndromes, catecholaminergic polymorphic ventricular 
tachycardias, Alzheimer’s and Huntington’s diseases for example (Bellin et al., 2012). 
hiPSCs have the same properties as hESCs: indefinite proliferation and ability to form 
all types of somatic cells of human body (Bellin et al., 2012). In addition to 
Yamanaka’s original method in which the integrative retroviral vectors were used, 
there are other methods developed for reprogramming hiPSCs, such as non-integrative 
vectors, synthetic mRNAs and small molecules (Bellin et al., 2012). The benefits of 
these are the avoidance of insertional mutagenesis and transgene reactivation, which 
lowers the risk of tumor formation and cancer risk and also variability between 
generated cell lines (Bellin et al., 2012). A con of these methods is usually lower 
efficiency (Bellin et al., 2012). 
 
2.4.1. hiPSC -derived CMs 
Human iPSCs can be differentiated into any somatic cell of the human body, 
including CMs. The differentiation of CMs, cardiogenesis and development of early 
cardiac mesoderm is controlled by three key families of protein growth factors: bone 
morphogenic proteins (BMPs), wingless/INT proteins (WNTs) and fibroblast growth 
factors (FGFs) (Mummery et al., 2012). Once these factors have initiated the 
cardiogenesis by inducing the cardiac mesoderm, complex combination of 
transcription factors and gene regulatory networks activate and begin a cardiac 
transcriptional program which leads to proliferation and maturation of CMs 
(Mummery et al., 2012). The ability to produce CMs in vitro, has been a great step 
forward when considering studies of cardiac diseases. It has been very difficult to 
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study cardiac diseases without this kind of model before, when one have had to rely 
on animal models and restricted amount of biopsies and tissue samples. There are 
three major different ways to differentiate CMs: embryoid body (EB) -method, 
monolayer culture and inductive co-culture (Mummery et al., 2012). There are usually 
cell line-to-cell line variation after differentiation, depending on the origin of the cells, 
reprogramming method and natural variation, resulting in a heterogenous population 
of rather immature cells (Bellin et al., 2012). 
 In EB-method, hiPSCs are either partially dissociated and cultured on standard 
cell culture plates or fully dissociated and cultured on special patterned plates to 
control EB formation (Mummery et al., 2012). EBs are spontaneous spheroid-like 3D-
structures of aggregated pluripotent stem cells with an ability to form all three germ 
layers (Mummery et al., 2012). EBs develop spontaneously beating CMs. In 
monolayer culture method, hiPSCs are dissociated and propagated as a simple 
monolayer- or matrix sandwich culture using Matrigel coated cell culture plates 
(Mummery et al., 2012). Addition of medium-Matrigel –mix on top of the cell layer 
creates the sandwich culturing structure (Mummery et al., 2012). With monolayer 
method, diffusion of nutrition and growth factors is more controlled and reproducible. 
Inductive co-culture method includes use of visceral endodermal-like END2 –cells 
which are used for their cell-signaling properties to promote cardiogenesis (Mummery 
et al., 2003). With this method, it is possible to get spontaneously beating 
differentiated CMs from relatively small amount of cells. Distinct differentiation-
methods require specific growth factors for optimized CM differentiation (Mummery 
et al., 2012). 
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3. Aims 
The aim of this study was to identify and compare the effects of uniaxial mechanical 
strain on HCM  –patient specific and control hiPSC -derived CMs, and learn to use 
the equipment and methods used in the study, such as cell culturing, Flexcell® –
apparatus, immunostaining, imaging and image analyses. 
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4. Materials & methods 
 
4.1. Patient-Specific hiPSC lines and culturing 
Four cell lines were used in this study: UTA.05105.HCMM, UTA.06108.HCMM, 
UTA.07108.HCMM and UTA.04602.WT. Three HCM-specific hiPSC lines 
(UTA.05105.HCMM (46, XX), UTA.06108.HCMM (46, XY) and 
UTA.07108.HCMM (46, XY))  have been generated from dermal fibroblasts of 
patients carrying a MYBPC3-Q1061X nonsense mutation. Control hiPSC line 
UTA.04602.WT (46, XX) has been generated from dermal fibroblasts of a healthy 55-
year-old female. The collection of biopsies for generating patient specific hiPSC-lines 
was approved by the ethical committee of Pirkanmaa Hospital District (Aalto-Setälä 
R08070) and written informed consent was obtained from all the donors. All hiPSC-
lines have been established by retroviral transfection of Oct3/4, Sox2, KLF4 and c-
Myc (Ohnuki et al., 2009). Characterization of hiPSCs included confirmation of 
mutations by qPCR, karyotype analysis, confirmation of gene expression by PCR and 
protein expression by immunocytochemistry. The pluripotency of hiPSC lines was 
confirmed by EB-formation and teratoma formation in mice. 
 Human iPSCs were cultured on mitomycin-C inactivated mouse embryonic 
fibroblasts (MEFs, 26 000 cells/cm
2
, Merck Millipore, MA, USA), which act as 
feeder cells to support growth of undifferentiated hiPSCs and to maintain their 
pluripotent state in hES-medium (Table 2). The undifferentiated state of hiPSCs was 
confirmed by morphologic analysis and undifferentiated colonies were passaged 
weekly on new MEFs. 
 
4.2. Cardiomyocyte differentiation 
Differentiation into CMs was carried out by co-culturing hiPSCs with murine visceral 
endoderm-like (END-2) cells (prof. Mummery, Humbrecht Institute, Utrecht, The 
Netherlands) (Mummery et al, 1991). END-2 –cells were mitomycin-C (Sigma 
Aldrich, MO, USA) inactivated (5µl/ml, 3h), trypsinized (Lonza, Switzerland) and 
plated on 12-well-plate (Nunc) 175 000 cells/well in END-2 medium (Table 3). END-
2 –cells were let to attach in 37°C overnight. 0% KO-SR hES –medium was changed 
to END-2 cells an hour before plating the hiPSCs. MEFs were removed and 
undifferentiated hiPSC -colonies were detached by scraping. hiPSC -colonies were 
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transferred on END-2 –cells ~30 colonies/well with minimal amount of culture 
medium. Cells were co-cultured in 37°C and 5% CO2. The 0% KO-SR hES -medium 
was changed at days 5, 8 and 12. At day 14, the medium was changed to 10% KO-SR 
hES –medium (Table 5) and changed 3 times a week. Cells were monitored with 
phase-contrast microscopy (Nikon Eclipse TS100 microscope, Imperx IGV-B1620M-
KC000 camera, JAI Camera Control Tool software). hiPSC -colonies formed 
spontaneously beating areas after around 15 days of co-culturing. 
 
Table 2. hES-medium (20% KO-SR DMEM). Pen/Strep = 10 U/ml Penicillin + 10 
U/ml Streptomycin. 
Component Quantity 
Knock-Out DMEM (Life Technologies)   
Knock-Out Serum Replacement (KO-SR, Life Technologies) 20% 
Non-essential amino acids (NEAA, Fischer Scientific) 1% 
GlutaMax (Life Technologies) 2 mM 
Pen/Strep (Fischer Scientific) 50 U/ml 
2-mercaptoethanol (Life Technologies) 0.1 mM 
Basic fibroblast growth factor (bFGF, R&D Systems) 4ng/ml 
 
Table 3. END-2 –medium. 
Components Quantity 
DMEM-F12 (Life Technologies)  
FBS (Immunodiagnostic) 7.5% 
NEAA 1% 
GlutaMax (Life Technologies) 2 mM 
Pen/Strep 50 U/ml 
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Table 4. 0% KO-SR hES –medium. 
Components Quantity 
KO-DMEM (Life Technologies)  
NEAA (Fischer Scientific) 1% 
GlutaMax (Life Technologies) 2 mM 
Pen/Strep (Fischer Scientific) 50 U/ml 
2-mercaptoethanol (Life Technologies) 0.1 mM 
Ascorbic acid ( Sigma Aldrich) 3.0 mM 
 
Table 5. 10% KO-SR hES –medium. 
Components Quantity 
KO-DMEM (Life Technologies)  
KO-SR (Life Technologies) 10% 
NEAA (Fischer Scientific) 1% 
GlutaMax (Life Technologies) 2 mM 
Pen/Strep (Fischer Scientific) 50U/ml 
2-mercaptoethanol (Life Technologies) 0.1 mM 
 
4.3. Dissociation of beating cardiomyocytes 
At day 16, spontaneously beating areas of cell colonies were cut and isolated with 
scalpel, collected in culture medium (10% KO-SR hES -medium) and dissociated 
(Mummery et al., 2003). Beating areas were washed in Low-Ca buffer (buffer 1, 
Table 6) at RT for 30 minutes and after that treated with collagenase A (Roche 
Diagnostics, Switzerland) (buffer 2, Table 6) at 37 ˚C for 45 minutes to one hour. 
Cells were incubated in KB medium (buffer 3, Table 6) (20µl of 1M glucose was 
added to 1ml of buffer 3) at RT for one hour. Aggregates/clumps were resuspended in 
EB-medium (20% FBS in KO-DMEM) (Table 7) by pipetting up and down several 
times against the bottom of the dish. This is a key step in dissociation, since 
aggregates, depending on the size, can be hard to break into single cell suspension, but 
at the same time, cells may be damaged. Single cell suspension was dealt to Uniflex-
membranes (3 beating areas/well) and gelatin coated cover slips (1 beating area/well) 
and let to attach at 37 ˚C for 30-45 minutes before loading up to the final amount of 
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EB-medium (3ml/well on Uniflex-plates and 800µl/well on 4-well-plates). Cells were 
cultured for three days before beginning of the stretching experiments. 
 For immunostaining control samples, 13mm cover slips were washed with 
70% ethanol and dried in laminar hood. Coverslips were coated with 0.1% gelatin at 
RT for one hour. 
 
Table 6. Components of dissociation buffers. 
 Low-Ca (1) Enzyme (2) KB (3) 
NaCl 12 ml (1M) 12 ml (1M) - 
CaCl2 - 3 µl (1M) - 
K2HPO4 - - 3 ml (1M) 
KCl 0.54 ml (1M) 0.54 ml (1M) 8.5 ml (1M) 
Na2ATP - - 2 mmol/L 
MgSO4 0.5 ml (1M) 0.5 ml (1M) 0.5 ml (1M) 
EGTA - - 0.1 ml (1M) 
Na pyruvate 0.5 ml (1M) 0.5 ml (1M) 0.5 ml (1M) 
Glucose 2 ml (1M) 2 ml (1M) 2 ml (1M) 
Creatine - - 5 ml (0,1M) 
Taurine 20 ml (0.1M) 20 ml (0.1M) 20 ml (0.1M) 
Collagenase A - 1 mg/ml - 
HEPES 1 ml (1M) 1 ml (1M) - 
pH correction NaOH NaOH - 
pH 6.9 6.9 7.2 
 
Table 7. EB-medium. 
Components Quantity 
KO-DMEM (Life Technologies)  
FBS (Immunodiagnostic) 10% 
NEAA (Fischer Scientific) 1% 
GlutaMax (Life Technologies) 2 mM 
Pen/Strep (Fischer Scientific) 50U/ml 
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4.4. Flexcell®-experiments 
Flexcell® is a commercially available device for culturing cells in a mechanically 
active environment. Flexcell® unit includes controller unit, compressor pump, PC and 
baseplate with collagen coated Uniflex®-plates with Arctangle® Loading Stations™ 
(Flexcell®, NC, USA). Pump, controller unit and baseplate are connected with tubes 
for carrying the negative pressure (suction). There are filters with containers for 
condensing moisture in the tubing between the baseplate and controller unit. PC and 
controller unit are connected with Ethernet-cable. The main idea how the uniaxial 
stretch is created with Flexcell®, is applying suction under the Uniflex-membranes so 
the membrane will stretch over the edges of loading stations (Figure 6). For creation 
of non-stretched control samples, loading stations can be left out and STOP-gums 
made of rubber placed under the Uniflex-membrane to prevent the stretching.  
 
 
Figure 6. Principle of concept: stretching of Uniflex-membranes. At rest, Uniflex-
membrane lies steady over the loading station. During stretching, vacuum drags 
Uniflex-membrane over the edges of loading station creating uniaxial strain. (Edited 
from Flexcell® Culture Plate & Loading Station User’s Manual) 
 
Total of five Flexcell®-experiments were carried out in this study. Because of the 
novel nature of this study, there were some practical differences between experiments. 
Regimens, methods and even equipment were changed and modified to make 
improvements in the study setup. Before use, baseplate and loading stations were 
washed with 70% EtOH. Loading stations were placed on the baseplate under each 
Uniflex-plate well. Silicone lubricant was used to minimize the friction between the 
loading stations and Uniflex-membranes. Additional filter for preventing the moisture 
reaching the controller unit was installed between experiments 4 and 5. Stretching 
with cells was carried out in an incubator at 37°C and 5% CO2 while the baseplate 
with its content was placed in it. At each time point, stretching had to be stopped for 
the duration of medium change for the remaining Uniflex-plates and sample 
acquisition. This took usually no more than 30 minutes. At each time point, one 
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Uniflex- and one 4-well-plate was removed from the stretching-experiment for 
immunostaining. Removed Uniflex-plate was replaced with an empty Uniflex-plate 
on the baseplate.  
 
4.4.1 The 1st Flexcell®-experiment: UTA.05105.HCMM 
The first Flexcell®-experiment was done using UTA.05105.HCMM cells (passage 
53) to get to know the Flexcell®-equipment and practice its use. The cells were 20 
days of age counted from the start of the END-2 co-culture. Time points for this first 
stretching were 1, 4, 7 and 9 days. These values were chosen quite randomly based on 
literature compiled at Flexcell® –website 
(http://www.flexcellint.com/PDF/FlexcellPublications.pdf). Coverslip-controls were 
not used in this experiment, because Uniflex-membranes’ autofluorescense was not 
yet observed. Total of 72 beating areas were cut, dissociated and plated on Uniflex-
plates. On each Uniflex-plate, three wells were blocked with STOP-gums and used as 
controls, and three wells were stretched. EB-culture medium was changed 3 times a 
week. Regimen used for stretching is shown on the Table 8. Proteins studied in this 
experiment were the following: cardiac troponin-T (cTnT), MyBP-C, α-actinin and 
connexin-43. 
 
Table 8. Regimen used during 1
st
 and 2
nd
 Flexcell® stretching on 
UTA.05105.HCMM. 
step wave form frequency (Hz) elongation % time 
1 sin 0.5 2.5 3:20 
2 sin 0.5 5 3:20 
3 sin 1 7.5 3:20 
4 sin 1 10 4, 7, 11 and 14d 
 
4.4.2. The 2nd Flexcell®-experiment: UTA.05105.HCMM 
The second Flexcell®-experiment was done using UTA.05105.HCMM cells (passage 
53, age 20d). The time points were chosen as 4, 7, 11 and 14 days, based on the 
images of the first Flexcell®-experiment (data not shown). These time points were 
used in the rest Flexcell®-experiments. Total of 84 beating areas were cut, dissociated 
and plated on four Uniflex-plates and 8 coverslips on four 4-well-plates. On each 
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Uniflex-plate, two wells were blocked with STOP-gums and used as controls, and 
four wells were stretched. Two cover slips on each 4-well-plate were prepared as 
controls for immunostaining, since the first Flexcell®-experiment results showed 
autofluorescence on Uniflex-membranes. EB-culture medium was changed 3 times a 
week. Regimen used for stretching was the same as in the first experiment (Table 8). 
Proteins studied in this experiment were the following: cTnT, MyBP-C, α-actinin, 
connexin-43 and in the last time point also atrial and ventricular myosin light chains 
(MLC2a and MLC2v respectively). 
 
4.4.3. The 3rd Flexcell®-experiment: UTA.06108.HCMM 
The third Flexcell®-experiment was done using UTA.06108.HCMM cells (passage 
18, age 20d). The time points were the same as in the previous experiment: 4, 7, 11 
and 14 days. Total of 80 beating areas were cut, dissociated and plated on four 
Uniflex-plates and 8 coverslips on four 4-well-plates. On each Uniflex-plate, two 
wells were blocked with STOP-gums and used as controls, and four wells were 
stretched. Two cover slips on each 4-well-plate were prepared as controls for 
immunostaining. EB-culture medium was changed 3 times a week. Regimen used for 
stretching was altered a bit and is shown in table 9. Proteins studied in this experiment 
were the following: cTnT, MyBP-C, α-actinin, connexin-43, MLC2a, MLC2v, αTM 
and Ki-67.  
 
Table 9. Regimen used in 3
rd
 Flexcell® stretching on UTA.06108.HCMM. 
step wave form frequency (Hz) elongation % time 
1 sin 1 10 4, 7, 11 and 14d 
 
4.4.4. The 4th Flexcell®-experiment: UTA.07801.HCMM 
Uniflex-membranes were pre-stretched for 24 hours before plating the dissociated 
CMs on them. Regimen for pre-stretching is shown in Table 10. Investigation of 
autofluorescense in Uniflex-membranes (lot#120313) showed that stretching the 
membrane decreased the level of autofluorescence shown in immunostainings. The 
fourth Flexcell®-experiment was done using UTA.07801.HCMM cells (passage 23, 
age 20d). The time points were 4, 7, 11 and 14 days. Total of 80 beating areas were 
cut, dissociated (buffer 2 incubation 70min) and plated on four Uniflex-plates and 8 
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coverslips on four 4-well-plates. On each Uniflex-plate, two wells were blocked with 
STOP-gums and used as controls, and four wells were stretched. Two cover slips on 
each 4-well-plate were prepared as controls for immunostaining. EB-culture medium 
was changed 3 times a week. Regimen used for stretching was altered and is shown in 
table 10. Proteins studied in this experiment were the following: cTnT, MyBP-C, α-
actinin, MLC2a, MLC2v, αTM and Ki-67.  
 
Table 10. Regimen used for pre stretching of Uniflex-membranes and 4
th
 Flexcell®-
stretching on UTA.07801.HCMM.  
step wave form frequency (Hz) elongation % time 
1 sin 1 7 4, 7, 11 and 14d 
 
4.4.5. The 5th Flexcell®-experiment: UTA.04602.WT  
Uniflex-membranes were pre-stretched for 5 days before plating the dissociated CMs 
on them. Regimen for pre-stretching is shown in Table 10. The fifth Flexcell®-
experiment was done using UTA.04602.WT cells (passage 29, age 20d). The time 
points were 4, 7, 11 and 14 days. Total of 88 beating areas were cut, dissociated and 
plated on four Uniflex- and coverslips on four 4-well-plates. On each Uniflex-plate, 
two wells were blocked with STOP-gums and used as controls, and four wells were 
stretched. Four cover slips on each 4-well-plate were prepared as controls for 
immunostaining. EB-culture medium was changed 3 times a week. Regimen used for 
stretching is shown in table 11. Proteins studied in this experiment were the 
following: cTnT, MyBP-C, α-actinin, MLC2a, MLC2v, αTM and Ki-67. 
 
Table 11. Regimen used for 5
th
 Flexcell®-experiment on UTA.04602.WT. 
step wave form frequency (Hz) elongation % time 
1 sin 0.5 3 3 min 
2 sin 0.5 5 5 min 
3 sin 1 7 4, 7, 11 and 14d 
 
4.5. Immunocytochemistry: double fluorescence staining protocol 
All the steps in the double fluorescence staining protocol were performed for all 
samples on Uniflex -membranes and coverslips. After removing one Uniflex- and 4-
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well-plate from the stretching experiment, EB-medium was aspirated and the samples 
were washed with 1xPBS (0.01M, pH7.4, Dulbecco’s phosphate buffer saline, BE17-
515F, Lonza) two times at RT for 5min. All the samples were fixed with 4% 
paraformaldehyde (PFA, Sigma-Aldrich) for 20min at room temperature (RT) as soon 
as possible (to prevent the effects of stretching from disappearing). PFA stored in 4°C 
was warmed to RT before applying. After fixation, the samples were washed two 
times with 1xPBS for 5min. Immunostainings were done immediately or samples 
were stored in PBS at +4°C for few days. Non-specific binding of the antibody was 
blocked and cells were permeabilized for 45 min at RT by using 10% NDS (normal 
donkey serum, Merck Millipore), 0.1% TritonX-100 (Sigma Aldrich), 1% BSA 
(Sigma Aldrich) in PBS. Samples were washed with 1% NDS, 0.1% TritonX-100, 1% 
BSA before adding primary antibody mixtures. Because of the large sample area of 
the Uniflex-membrane, Pap-Pen (G.Kisker, MKP-1) was used to border the 
application area of primary antibody mixtures for cost-efficiency. Total of five 
different primary antibody mixtures containing two primary antibodies (Table 12) 
produced in different animals were used: anti-cTnT and anti-MyBP-C, anti-cTnT and 
anti-α-actinin, anti-α-actinin and anti-connexin-43, anti-αTM and anti-Ki-67 (protein 
marker for cell division), anti-MLC2a and anti-MLC2v. Mixtures of primary 
antibodies were prepared in 1% NDS, 0.1% TritonX-100, 1% BSA in PBS. Primary 
antibodies were incubated on cells in +4°C overnight. On the next day, samples were 
washed three times with 1% BSA in PBS for 5min before applying secondary 
antibodies (Table 13). Alexa Fluor 488 and 568 were used in each mixture. Secondary 
antibody mixtures were prepared in 1% BSA in PBS. Pap-Pen was applied again on 
Uniflex-membranes to reinforce the bordering of the sample area. Samples were 
incubated in secondary antibody mixtures for 1hr in RT protected from light. To 
remove unbound antibodies, samples were washed three times with 1xPBS for 5min 
and two times with phosphate buffer working solution (0,01M, pH7.4) for 5min. The 
back of the Uniflex-membranes were washed to remove the silicone lubricant with 
70% EtOH and by gently sweeping with cellulose paper. Sample areas from Uniflex-
membranes were cut with scalpel and placed on 76x26mm microscope slides 
(Menzel-Gläser, Thermo Scientific) cells on top and mounted with Vectashield 
(Vector Laboratories Inc, H-1200), containing 49, 6-diamidino-2-phenylindole 
(DAPI) for staining nuclei, and thin 24x50mm microscope cover slips (Menzel-
Gläser, Thermo Scientific). Coverslips containing control samples were dried in the 
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air and mounted on 76x26mm microscope slides with Vectashield and standard nail 
polish (edges only). 
 
4.6. Imaging 
Imaging of the immunostained samples was carried out with Zeiss AxioScope A1 
fluorescent microscope and Zeiss AxioCam MRc5 camera. The microscope was 
operated with Zeiss’ Zen 2012 software via PC. 10x, 20x, and 40x air objectives were 
used for imaging. 
 
Table 12. Primary antibodies. 
Antibody Origin Dilution Manufacturer 
cTnT goat IgG 1:2000 Abcam (ab64623) 
MyBP-C mouse IgG 1:400 Santa Cruz (sc-166081) 
α-actinin mouse IgG 1:1500 Sigma Aldrich (A7811) 
Connexin 43 rabbit IgG 1:1000 Sigma Aldrich (C6219) 
MLC2a mouse IgG 1:200 Synaptic Systems (311011) 
MLC2v rabbit IgG 1:200 Protein Tech (10906-1-AP) 
αTM mouse IgG 1:200 Santa Cruz (sc-73225) 
Ki-67 rabbit IgG 1:600 Millipore (AB9260) 
 
Table 13. Secondary antibodies. 
Antibody Origin Dilution Manufacturer 
Alexa Fluor 488 donkey anti-mouse 1:800 Life Technologies (A21202) 
Alexa Fluor 488 donkey anti-rabbit 1:800 Life Technologies (A21206) 
Alexa Fluor 568 donkey anti-goat 1:800 Life Technologies (A11057) 
Alexa Fluor 568 goat anti-mouse 1:800 Life Technologies (A11004) 
 
4.7. Image analysis 
Images from all three filters (DAPI, Alexa Fluor 488, Alexa Fluor 568) were stacked 
with Adobe Photoshop CS4. Proportions of Ki-67, MLC2a and MLC2v positive and 
negative cells were counted from single cells. Each individual sarcomere proteins’ 
organization was analyzed from each image in which the protein was stained. 
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Structural organizations of proteins were categorized into three classes: disorganized 
(>75% of the protein disorganized or >50% punctuate expression), organized (protein 
organized or aligned >50% of the cell) and circular (protein localized circularly) 
(Figure 8). Alignment of single cells was analyzed with degree grid placed over the 
images with Adobe Photoshop CS4 (Figure 7). Cells aligned within +/– 45 degrees 
from the vertical 0° were categorized as vertical and cells aligned within +/- 44 
degrees from the horizontal 0° were categorized as horizontal cells (Figure 7). Cells 
categorized as “others” were morphologically irregular, square in shape or round. 
 
 
Figure 7. Degree grid used to determine the cell alignment from single cells in 
images. A = vertical, B = horizontal. 
 
4.8. Statistical analysis 
Error bars for the graphs were calculated as standard error of the mean (SEM), where  
    
      
√ 
 
st.dev is standard deviation and n is the number of observations/samples. P-values 
were calculated using Chi-squared test with MS Excel. 
 
4.9. Cell area analysis 
 
Cell area analysis was done by collaborating researcher at University of Tampere, 
School of information sciences. A Matlab –based software was developed for this 
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purpose only, by Jyrki Rasku, PhD. All single cells were analysed from all 
immunostained images. 
 
 
Figure 8. Examples of each four proteins (αTM, α-actinin, cTnT and MyBP-C) 
categorized into the three categories (disorganized, organized and circular). 
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5. Results 
 
In this study, HCM –patient specific and WT hiPSC –derived CMs were stretched 
with Flexcell® and samples were stained using immunocytochemistry, imaged and 
analyzed. Stretched samples were compared with controls and HCM CMs with WT 
CMs. Examples of immunostained CMs are shown in Figure 9. Because of small n-
values in some HCM cell line samples, in each analyze, results from each HCM cell 
line were combined to view their results as one population. 
 
 
Figure 9. Examples of immunostained control and stretched WT and HCM cells.  
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5.1. Cell proliferation 
Cell proliferation was studied in three cell lines: UTA.07801.HCMM, 
UTA.06108.HCMM and UTA.04602.WT (Figure 10). CMs were stained with anti- 
αTM and anti- Ki-67 primary antibodies. Ki-67 is a protein localizing in nucleus 
during interphase and it can be used as a cell division marker (Scholzen & Gerdes, 
2000). Cells which expressed both proteins were counted as proliferating CMs. In 
UTA.07801.HCMM cell line, 52.5% (n=63) of control cells and 25.1% (n=141) of 
stretched cells were Ki-67 positive. The proliferation was relatively 52.2% lower in 
stretched than in control samples. In UTA.06108.HCMM cell line, the amount of 
proliferating cells was 73.1% (n=65) in control and 44.3% (n=316) in stretched 
samples. The proliferation was relatively 39.4% lower in stretched than in control 
samples. In UTA.04602.WT cell line, the amount of proliferating cells was 74.9% 
(n=101) in control and 53.2% (n=198) in stretched samples. The proliferation was 
relatively 29.0% lower in stretched than in control samples (Figure 10A).  When 
comparing HCM and WT cells (Figure 10B), stretching decreases proliferation in 
both. Because of great SEM values, especially in stretched populations, it can not be 
said for sure how much HCM effects on cell proliferation.
 
 
Figure 10. Cell proliferation. (A) Stretching decreases cell proliferation in all cell 
lines. (B) Stretching decreases cell proliferation in HCM and WT cells. (C) Example 
of Ki-67 positive and negative CMs. (D) Numbers of Ki-67 positive cells in control 
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and stretched samples for each cell line. (*) p<0.002. Error bars show standard error 
of the mean (SEM). 
 
5.2. Sarcomere protein organization 
In this study, organization of αTM (Figure 11), α-actinin (Figure 12), MyBP-C 
(Figure 13) and TnT (Figure 14) were analyzed. The results are presented for each 
individual cell line and as HCM and WT cells, where HCM cell lines are combined 
together. Statistically significant results were found.  
 Stretching increased 15.0% circular organization of αTM significantly in 
UTA.06108.HCMM cell line (Figure 11A). UTA.04602.WT cells responded to 
stretching by decrease of 27.4% in circular and increase of 33.7% in organized αTM 
structures (Figure 11C). When results from HCM cell lines were combined, no 
significant changes were found (Figure 11D). 
 Stretching increased 47.8% disorganized and decreased 50.0% organized 
structure of α-actinin significantly in UTA.05105HCMM cell line (Figure 12A). In 
UTA.04602.WT cell line, stretching significantly decreased 10.1% of circular and 
increased 14.8% disorganized structure of α-actinin (Figure 12D). When results from 
HCM cell lines were compiled, no significant changes were found (Figure 12E). 
 In UTA.07801.HCMM cell line, stretching significantly decreased 21.9% 
disorganized and increased 51.3% organized structure of MyBP-C (Figure 13B). In 
WT cells, significant decrease of 11.9% in circular MyBP-C organization was found 
(Figure 13D). When observing all HCM cells, significant decreases of 7.3% in 
disorganized and 0.8% in organized structures of MyBP-C was found (Figure 13E).  
 In UTA.07801.HCMM cell line, stretching significantly decreased 16.9% 
disorganized and increased 27.0% organized structure of TnT significantly (Figure 
14C). In WT cells, all the structural organization changes of TnT induced by 
stretching were significant: 17.5% decrease in circular, 4.6% decrease in disorganized 
and 22.1% increase in organized structures were found (Figure 14D). In HCM cell 
population significant decrease of 3.8% was found in disorganized TnT structures 
after stretching (Figure 14E). 
 Differences in HCM and WT controls were studied statistically. Circular 
organization of αTM was significantly higher (p=2.14x10-6), but organized structures 
were significantly lower in WT than HCM control cells (p=8.25x10
-6
) (Figure 11D). 
Circular organization of α-actinin was significantly higher (p=0.0052), but 
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disorganized structures were significantly lower in control WT than control HCM 
cells (p=0.0016) (Figure 12E). There were significantly less disorganized structures of 
MyBP-C in WT than HCM control cells (p=3.19x10
-4
) (Figure 13E). Circular 
organization of TnT was significantly higher (p=0.0012), but disorganized structures 
were significantly lower in WT than HCM control cells (p=0.0019) (Figure 14E). 
Also, there were significantly less disorganized structures of cTnT in WT than HCM 
control cells (p=0.0064) (Figure 14E). 
 
Figure 11. Alpha-tropomyosin organization. Organization of αTM (A-C) in each cell 
line. (D) HCM-cells compared to WT-cells. (E) Cell amounts in each category. (*) 
p<0.05, (**) p<0.01. Error bars show standard error of the mean (SEM). 
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Figure 12. Alpha-actinin organization. (A-D) Organization of α-actinin in each cell 
line. (E) HCM-cells compared to WT-cells. (F) Cell amounts in each category. (*) 
p<0.05, (**) p<0.01. Error bars show standard error of the mean (SEM). 
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Figure 13. Myosin binding protein C organization. (A-D) Organization of MyBP-C in 
each cell line. (E) HCM-cells compared to WT-cells. (F) Cell amounts in each 
category. (*) p<0.05, (**) p<0.01. Error bars show standard error of the mean (SEM). 
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Figure 14. Troponin T organization. (A-D) Organization of TnT in each cell line. (E) 
HCM-cells compared to WT-cells. (F) Cell amounts in each category. (*) p<0.05, (**) 
p<0.01. Error bars show standard error of the mean (SEM). 
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5.3. Cell alignment 
CMs from immunostained samples were categorized as vertical (alignment against the 
axis of strain) and horizontal (alignment along the axis of strain). Stretching 
significantly induced vertical alignment both in HCM and WT cells (Figure 15). In 
HCM cells, the increase was 21.4% (controls n=225, stretched n=518) compared to 
24.3% (controls n=311, stretched n=413) in WT cells (Figure 15E). When studying 
individual cell lines, increases in vertical alignment were 16.8% (controls n=12, 
stretched n=141), 19.7% (controls n=111, stretched n=234), 30.2% (controls n=102, 
stretched n=143) and 24.2% (controls n=311, stretched n=413) in 
UTA.05105.HCMM, UTA.06108.HCMM, UTA.07801.HCM and UTA.04602.WT 
respectively (Figure 15A-D). In individual cell lines, decreases in horizontal 
alignment were 7.2% (controls n=12, stretched n=141), 17.9% (controls n=111, 
stretched n=234), 10.3% (controls n=102, stretched n=143) and 10.4% (controls 
n=311, stretched n=413) in UTA.05105.HCMM, UTA.06108.HCMM, 
UTA.07801.HCM and UTA.04602.WT respectively (Figure 15A-D). Trending of the 
effect of stretch over time to HCM and WT cells can be seen in Figure 16A-D. These 
results implicate that the uniaxial stretching increases vertical and decreases 
horizontal cell alignment in HCM and WT cell lines. 
 
5.4. Multinuclearism 
Multinuclearism was analyzed from each single CM by counting the amount of nuclei 
from images of immunostained samples (Figure 17). HCM and WT cells behave 
differently when it comes to multinuclear cell development (Figure 17A-B). HCM 
control cells develop increasing amounts of multiple nuclei during 2 weeks compared 
to stretched HCM cells, which keep the amount approximately the same. After 2 
weeks of stretching, WT cells have approximately the same amount of multinuclear 
cells than in the beginning. However, total amount of multinuclear WT cells is less in 
stretched samples than controls because of the decreasing trend during until day 11. 
When comparing HCM and WT cells in general (Figure 17C), we see that in both 
there are less multinuclear cells in stretched samples. Also, there are less multinuclear 
cells in WT than HCM cells, 17.9% (n=381) versus 43.7% (n=295) in controls and 
8.7% (n=554) versus 23.2% (n=767) in stretched samples. To conclude, HCM cells 
have more multinuclear cells than WT cells and stretching decreases the amount of 
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multinuclear cells significantly. There is significantly greater amount of multinuclear 
HCM than WT cells in control (p=2.80x10
-11
) and stretched (p=6.14x10
-12
) samples. 
 
 
Figure 15. Cell alignment. (A) No statistically significant differences in 
UTA.05105.HCMM –cell line. (B) Stretching significantly increases vertical 
alignment of UTA.06108.HCMM –cells. (C, D) Stretching significantly increasis 
vertical and decreases horizontal alignment in UTA.07801.HCMM- and 
UTA.04602.WT -cells. (E) Stretching significantly increases vertical alignment of 
both HCM and WT cells. (F) Amount of vertically and horizontally aligned cells in 
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each cell line. (*) p<0.05, (**) p<0.01.Error bars show standard error of the mean 
(SEM). 
 
 
Figure 16. Cell alignment at each time point. (A-D) Effect of stretching over time on 
HCM and WT cell alignment. (E) Amounts of vertical and horizontal aligned cells in 
each time point. 
 
 
5.5. Atrial and ventricular cardiomyocytes 
Percentages of MLC2a- and MLC2v -positive single CMs were calculated from 
images of immunostained samples. Ventricular adult CMs express both atrial and 
ventricular myosin light chains (Bird et al., 2003). Cells which expressed only MLC2a 
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were counted as atrial- and the rest expressing both or only MLC2v as ventricular 
CMs. In stretched samples, there were more atrial CMs than in control samples 
(Figure 18). In control HCM cells (n=109), there were no atrial CMs at all compared 
to the stretched HCM cells (n=177) in which there were 26.8%. In control WT cells 
(n=66), there were 3.0% and in stretched WT cells (n=48) 12.5% atrial CMs. All in 
all, there were more ventricular CMs in each sample. 
 
 
Figure 17. (C) Percentages of multinuclear cells in HCM and WT cells. Percentages 
of multinuclear cells in HCM (A) and WT (B) cells in each time point. (D) 
Multinuclear HCM and WT cells in control and stretched samples. (*) p=1.91x10
-8
, 
(**) p=7.01x10
-5
. Error bars show standard error of the mean (SEM). 
 
 
 
Figure 18. Atrial and ventricular cardiomyocytes in HCM and WT cells. (A) 
Percentages of atrial and ventricular CMs in control and stretched HCM and WT 
cells. (B) Example of atrial (red) and ventricular (green/red) CMs. (C) Amounts of the 
cells. (*) p=2.93x10
-7
, (**) p=0.0035. Error bars show standard error of the mean 
(SEM). 
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5.6. Cell area 
Cell areas were calculated from all four cell lines used in this study. Only single CMs’ 
cell areas were analyzed. Stretching increased cell area in WT cells 74.1-88.8% 
throughout the two weeks of stretching (Figure 19A). Stretching induced cell area 
growth faster during the first week of stretching in HCM cells, but in the end, the 
control HCM cells were 10.0% bigger than stretched HCM cells (Figure 19A). 
Control HCM cells were bigger than control WT cells. In the end of two weeks of 
stretching, HCM cells were 19.0% bigger than WT cells. 
 
 
 
Figure 19. (A) Average areas of the cells in each time point in WT and HCM cell 
lines. (B) Tables showing the values in graph, amount of cells in each sample and 
ratios of stretched/control average cell areas. 
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6. Discussion 
 
6.1. Study setup 
In most publications in which Flexcell® has been applied, murine CMs have been 
used, so this study with hiPSCs was somewhat novel in nature. The longest stretching 
periods in earlier publications using murine CMs was only 2 days (Boateng et al., 
2006; de Jonge et al., 2002; Facundo et al., 2012). In this study the longest stretching 
period was 2 weeks. With this kind of dramatic increase in stretching time period, 
added to that hiPSCs –derived CMs were used, the hopes of finding something new 
were high. The HCM patient specific hiPSC derived CMs with the mutation in 
MYBPC3 used in this study offer a great model to study different aspects of the 
disease. 
 One of the most important step in the study was the dissociation of the CMs. 
First of all, the trickiest part of dissociation is the up and down pipetting of the 
aggregate solution trying to get single cells. Depending on the cutting of the beating 
areas, there are various sizes of aggregates from which some are tougher than others. 
This step affects the survivability of the cells and the starting material volume greatly, 
since if the cells are handled too hard, they may be damaged and do not start growing 
and proliferating after plating. The 2
nd
 buffer incubation time in dissociation protocol 
was slightly increased from 45 minutes to one hour making aggregates dissociate 
better. It was noticed during this study, that the success of dissociation was greater in 
the last experiment than in the first one, resulting in more cells in the samples. 
 
6.2. Flexcell® 
The Flexcell® –apparatus was not well known in the research group before this study. 
There were some practical and technical issues along the study which more or less 
made things difficult. First of all, the controller unit is very prone to get damaged. 
While the compressor pump is operating, the tubes in which the air flows, condensate 
moisture over time. If the moisture reaches the controller unit, the sensors which 
measure the pressure, and regulate the elongation-% of the membrane, become 
dysfunctional. This leads to inappropriate pressure output of the pump and loss of 
function of the stretching. This happened during this study and it created a delay in 
53 
 
 
the process because the controller unit had to be sent for repair. After the repair, 
additional filter was added between the tubing and the controller unit to capture the 
moisture and preventing it reaching the electronics of the sensors. Secondly, during 
the whole study, the displayed elongation-% was never the same as the input in the 
operating software. The input in the regimen had to be increased in order to get the 
elongation-% that was wanted. In the regimen tables of this thesis, the elongation 
percentages are the ones displayed by the software. Also, the Flexcell® International 
Corporation Culture Plate & Loading Station™ User’s Manual sets the maximum 
elongation-% sustained by the Flexcell® to 12.2% which is about 90 kPa provided by 
the pump. In first experiments, a higher elongation-% of 10% was used, but it 
unfortunately was one reason behind the controller unit malfunction. It was concluded 
that stretching of 2 weeks with that high pressure, makes the moisture condensate 
more rapidly. 
 More severe problems was created by the autofluorescence of the Uniflex-
membranes. It was noticed after the first experiments that using the STOP-gums for 
creation of control (non-stretched) samples resulted in huge amount of 
autofluorescence which affected the images negatively. Also slighter amount of 
autofluorescence was noticed in some stretched Uniflex-membranes too. Throughout 
the study 21 of 104 samples were unable to be imaged because of the 
autofluorescence. During the first experiment there was no autofluorescence because 
higher elongation-% (10%) was used. After the controller unit repair, the elongation-
% was dropped to 7% which resulted in increased autofluorescence in samples. It was 
decided to try to fix the problem with pre-stretching the Uniflex-membranes before 
plating the cells. Apparently, the 10% elongation during pre-stretching is more 
effective removing the autofluorescence than 7% elongation. 
 
6.3. Immunostainings 
Exceptionally, older anti-connexin-43 primary antibody was probably used staining 
the 11d and 14d time point samples in 3
rd
 Flexcell®-experiment with 
UTA.06108.HCMM cell line, resulting to failed staining. The connexin-43 was not 
included in any analyses and was replaced by other antibody combination in later 
experiments. 
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 Cells stained with primary antibody for Ki-67 were analyzed for cell 
proliferation. Ki-67 is a cell division marker which is localized exclusively within the 
nucleus during interphase and on the surface of chromosomes during mitosis 
(Scholzen & Gerdes, 2000). It is present in all active cell cycle phases, leaving resting 
cells unstained. Even though the phases of the cell cycle could be, in at least some 
extent, determined by analyzing the localization pattern of Ki-67 within the nucleus, 
in this the focus was on the presence of the protein in the nuclei and it was used as a 
proliferation marker only. 
 In three cell lines (UTA.06108.HCMM, UTA.07801.HCMM and 
UTA.04602.WT), cells were stained with anti-MLC2a and anti-MLC2v primary 
antibodies to distinguish atrial and ventricular CMs from each other. Surprisingly, 
some cells showed binding of both MLC2a and MLC2v antibodies to the same cell. 
This was thought to be a consequence of nonspecific binding of the antibodies or cells 
being immature. Interestingly, it has been shown earlier that ventricular adult CMs, 
obtained from human biopsies, express both atrial and ventricular myosin light chains 
(Bird et al., 2003). It may be possible that in disease state like HCM, this kind of 
expression takes place (Cummins, 1982). The results suggest that hiPSC derived 
ventricular CMs also express both MLC2a and MLC2v. There were very few atrial 
CMs in control samples. The results suggest that stretching increases the amount of 
atrial CMs. This could provide a novel strategy for development of more mature 
tissue crafts in the future, with more even ratio of atrial and ventricular CMs in them. 
 
6.4. Effects of uniaxial strain on hiPSC –derived CMs 
Cell proliferation was lower in stretched samples than in control samples suggesting 
that the mechanical stress was too much for the cells. In some images taken from 
stretched samples, there were parts of broken cells visible. Surprisingly, the 
proliferation was higher in UTA.06108.HCMM cells than in UTA.07801.HCMM 
cells even though the mechanical stress during the stretching was higher (elongation-
% 10% and 7% respectively). On the other hand, hiPSC derived CMs maturate over 
time in culture and should resemble more the mature adult CM phenotype which is 
known to proliferate very little if at all (Robertson et al., 2013). 
 Organizational analysis of each stained sarcomere protein did not reveal 
consistent patterns of behavior of sarcomere structure under mechanical stress. Each 
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CM’s individual state of maturity, affecting the cell morphology, could be even more 
major factor in the organization of sarcomeres in these cells than the stretching. 
Immature CMs are usually round whereas more mature CMs are square, longitudinal 
or irregular in shape (Robertson et al., 2013). From the four analyzed sarcomere 
proteins, α-actinin and MyBP-C showed interesting features in some CMs. There 
were punctuate α-actinin structures in some CMs, which were categorized in the 
disorganized category. This could be caused by excessive amount of mechanical 
stress to the cells, leading to a breaking of α-actinin connections between sarcomere 
units. Similar punctuate behavior of α-actinin have been reported earlier in DCM -
patient specific hiPSCs (Sun et al., 2012). 
 Organization of MyBP-C was the biggest question since the HCM cell lines 
used in this study had the MYBPC3 Finnish founder mutation in them. Surprisingly, 
from the immunostained images, it was noticed that the expression of MyBP-C was 
incomplete throughout some cells, some even lacking it completely. This was 
observed both in HCM and WT cells, even in control samples. The MyBP-C lacking 
cells still stained positive for cTnT which identified them as CMs. Possibilities for 
this kind of incomplete staining/expression of MyBP-C in these cells could be caused 
by malfunction of the anti- MyBP-C primary antibody, variation in CM permeability 
for antibodies or sarcomere protein turnover in CMs. The primary antibody function 
could be tested by using another one for comparison and the permeability of CMs 
could be increased by increasing concentration of TritonX-100 in staining protocol. 
Theory about MyBP-C turnover needs further investigation, still it could be possible 
that the truncated MyBP-C has increased degradation rate and only the newly 
synthetized protein in the proximity of nucleus becomes stained (Figure 9). However, 
WT cells, which are supposed to have perfectly normal MyBP-C structure, showed 
same kind of expression in immunostained images. Interactions between actin and 
MyBP-C are essential for maintenance of sarcomere assembly: MyBP-C without actin 
binding domain was shown to be stable but with limited incorporation into sarcomere 
structure, whereas cardiac dysfunction was observed with disrupted MyBP-C – actin 
interaction (Bhuiyan et al., 2012; Kulikovskaya et al., 2003). One reason for 
interruption of MyBP-C – actin interactions could be stress overload. Under cardio- 
and cytotoxic conditions, carbonylation and degradation of MyBP-C was observed 
(Aryal et al., 2014). 
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 One of the hypotheses in the beginning of the study was that the uniaxial 
stretching could be used to align cells in desirable fashion. Parallel alignment of CMs 
is an important factor for the synchronous function in living tissue (Bers 2001; Severs, 
2000). If cells could be aligned in preferred manner, it could improve the maturation 
of the cells and help creating more authentic and functional tissue crafts in the future 
(Lundy et al., 2013). The results implicate that the cells tend to align across the axis of 
uniaxial strain. 
 There were more multinuclear cells in control samples than stretched samples 
and in HCM than WT cells. Results suggest that stretching decreases the amount of 
multinuclear cells. Mature adult CMs are usually bi- or multinucleated because of the 
lack of cytokinesis after embryonic development and birth (Clubb & Bishop, 1984, 
Robertson et al., 2013). It has been thought that polyploidization is caused by a 
special cellular program that protects the cells from uncontrolled proliferation or 
apoptosis (Storchova & Pellman, 2004). This kind of program is thought to protect the 
working myocardium and enable CMs to adapt to disease condition such as in 
hypertrophic growth (Liu et al., 2010). 
  Interesting results were obtained from cell area analysis: control WT 
cells are smaller than control HCM cells and stretching increases WT cell area greatly 
compared to HCM cells after two weeks of stretching. Since HCM cells are bigger 
than WT cells to begin with, the change in cell area is greater in WT cells. As 
described earlier, mechanotransduction in CMs can lead to activation of growth 
signals (Sadoshima and Izumo, 1997). HCM cells may have already, because of the 
disease caused by gene mutation in sarcomeric protein leading to altered cell function, 
accommodated themselves to a state in which the cell size is bigger.  
 All the analyses presented here were based on looking into single cells in the 
samples. However, because of the method how cells were processed before plating, 
there were cell aggregates in samples also. No quantitative analysis were made but 
two different observations were noticed: first, the cell clumps tended to scatter in the 
stretched samples. It could be a consequence of the excessive force of stretching, 
which resulted tearing the cells apart. The scattered cells next to each other showed 
puzzle –like morphology, which indicated that they might have been in close cell-to-
cell connections with each other. Second, the cell clumps seemed to be more normal 
in sarcomere structure than single cells in general. This may be a result of gap 
junctions formed between CMs by connexins, which allows signaling between the 
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cells. The signaling between cells may lead to compensatory effects. Same kind of 
behavior was reported earlier in DCM patient specific hiPSCs (Sun et al., 2012). 
 
6.5. hiPSCs as a disease model 
hiPSCs offer an easier setup of disease modeling and drug screening than ESCs and 
do not have the ethical issues. One of the benefits with hiPSCs is the opportunity to 
create controls from the same patient by “curing” a mutation which allows use of 
relevant controls with the same ethnic genotype, known as isogenic controls (Soldner 
et al., 2011). This kind of setup allows experiments to be performed under genetically 
defined conditions. Eventually, hiPSCs may reduce use of animal models. Working 
with animal models is expensive and the data obtained from animal studies do not 
always reflect the outcome in humans. However, there are some issues considering 
hiPSCs authenticity, such as immaturity and incomplete penetrance of the disease 
being modeled, leading to different phenotypes with same mutations (Bellin et al., 
2012). On the other hand, this kind of behavior can be considered as an opportunity to 
study the effect of background and epigenetics.  
 hiPSC derived CMs are structurally and functionally immature and they have 
fetal-like properties (Keung et al., 2014; Robertson et al., 2013). The maturation 
seems to depend greatly on the cultivation time in culture and also culture conditions 
and method of differentiation (Keung et al., 2014; Lundy et al., 2013; Robertson et al., 
2013). hiPSC CMs exhibit different morphologies, structure, proliferation, gene 
expression, metabolism, bioenergetics, electrophysiological properties and calcium 
handling (Robertson et al., 2013).  
 Systematic quantification of similarities and differences in hiPSC derived CMs 
and adult CMs is complicated because of the fact that different studies use diverse 
methods, culture conditions and cell lines of origins. CM differentiation from hiPSCs 
takes advantage of co-culturing with other cells and various culture conditions. The 
type of differentiation has effects on the outcome of CM maturation but the exact 
mechanisms are poorly known. With various differentiation methods, CMs with 
different properties are acquired. CMs differentiate further into atrial-, ventricular- 
and pacemaker –cells, which are obtained in different proportions depending on 
differentiation method (Robertson et al., 2013). Unfortunately, the effectiveness of 
CM differentiation methods are still very low. Individual research groups, though, 
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may have their own adjustments and tweaks to differentiation methods and protocols. 
This kind of constant developing and studying of the protocols hopefully leads to a 
more effective differentiation methods in the future. Also, different surface materials 
can have an effect on the morphology and maturity of the cells. Studies have been 
carried out by testing different topographical surfaces for cell culturing in 2D and 3D 
models (Bian et al., 2014; Liau et al., 2011; Rao et al., 2013). 
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7. Conclusions 
 
In this study, effects of uniaxial mechanical strain on HCM –patient specific and 
control hiPSC –derived CMs were studied. Mechanical uniaxial stretching of HCM -
patient specific and control hiPSC -derived CMs decreases cell proliferation, has 
effects on sarcomere protein organization, increases alignment against the axis of the 
strain, decreases multinuclearism, increases proportion of atrial cardiomyocytes in 
culture and increases wild type cells’ size. 
 In the future, more studies of the functionality, morphology and maturity of 
hiPSC –derived CMs are needed to discover the true potential of hiPSC –applications 
in cardiac disease modeling. The immaturity of hiPSC –derived CMs yet restrict their 
use in clinical applications. More effective differentiation methods, tissue engineering 
studies and advanced culturing conditions are needed to provide new strategies to 
develop more mature hiPSC –derived CMs for cardiac regenerative medicine. 
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